Restructuring the ONYX-015 adenovirus by using spike protein genes from SARS-CoV-2 and MERS-CoV: Possible implications in breast cancer treatment

Parmar, Hamendra Singh; Nayak, Aakruti; Kataria, Shreya; Tripathi, Versha; Jaiswal, Pooja; Gavel, Pramod K.; Jha, Hem Chandra; Bhagwat, Shivani; Dixit, Amit Kumar; Лукашевич, В. С.; Das, Apurba Kumar; Sharma, Rajesh

doi:10.1016/j.mehy.2021.110750

Cited by 4 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Research on HSV-1 in the herpesvirus group has shown that it has a positive effect on the treatment of tumor cells. HSV has demonstrated a significant effect on melanoma ( Senzer et al, 2009 ; Kaufman et al, 2010 ; Andtbacka et al, 2015 ; Johnson et al, 2015 ; Killock, 2015 ; Puzanov et al, 2016 ; Chesney et al, 2018a , b ; Andtbacka et al, 2019 ; Yun et al, 2022 ), breast cancer (BC; Teshigahara et al, 2004 ; Gholami et al, 2014 ; Fan et al, 2021 ; Parmar et al, 2022 ), HNC ( Mace et al, 2008 ; Harrington et al, 2010 ), glioblastoma ( Papanastassiou et al, 2002 ; Kanai et al, 2011 ; Patel et al, 2016 ; Omar et al, 2021 ), PRAD ( Wang et al, 2019 ), peritoneal cancer ( Nakano et al, 2005 ), colorectal cancer (CC; Kemeny et al, 2006 ; Geevarghese et al, 2010 ), pancreatic cancer (PAAD; Nakao et al, 2011 ; Kelly et al, 2016 ; Hirooka et al, 2018 ), solid tumor ( Zhang et al, 2021 ), and other tumor cells. Currently, there are several strategies for HSV virus transformation, including deleting UL39 and other genes required for replication in nondividing cells and deleting the neural virulence gene ICP34.5 and immune escape-related gene ICP47 ( Campadelli-Fiume et al, 2011 ).…”

Section: Development Species and Research Progress Of Oncolytic Virusesmentioning

confidence: 99%

Development and application of oncolytic viruses as the nemesis of tumor cells

et al. 2023

View full text Add to dashboard Cite

Viruses and tumors are two pathologies that negatively impact human health, but what occurs when a virus encounters a tumor? A global consensus among cancer patients suggests that surgical resection, chemotherapy, radiotherapy, and other methods are the primary means to combat cancer. However, with the innovation and development of biomedical technology, tumor biotherapy (immunotherapy, molecular targeted therapy, gene therapy, oncolytic virus therapy, etc.) has emerged as an alternative treatment for malignant tumors. Oncolytic viruses possess numerous anti-tumor properties, such as directly lysing tumor cells, activating anti-tumor immune responses, and improving the tumor microenvironment. Compared to traditional immunotherapy, oncolytic virus therapy offers advantages including high killing efficiency, precise targeting, and minimal side effects. Although oncolytic virus (OV) therapy was introduced as a novel approach to tumor treatment in the 19th century, its efficacy was suboptimal, limiting its widespread application. However, since the U.S. Food and Drug Administration (FDA) approved the first OV therapy drug, T-VEC, in 2015, interest in OV has grown significantly. In recent years, oncolytic virus therapy has shown increasingly promising application prospects and has become a major research focus in the field of cancer treatment. This article reviews the development, classification, and research progress of oncolytic viruses, as well as their mechanisms of action, therapeutic methods, and routes of administration.

show abstract

Section: Development Species and Research Progress Of Oncolytic Virusesmentioning

confidence: 99%

Development and application of oncolytic viruses as the nemesis of tumor cells

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Recently, we have comprehensively reviewed the crosstalk between diabetes and breast cancer pathways and highlighted the importance of the repurposing of incretinbased antidiabetic therapies in breast cancer (Parmar et al, 2021;Parmar et al, 2022;Jaiswal et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

Anti-cancer effects of sitagliptin, vildagliptin, and exendin-4 on triple-negative breast cancer cells via mitochondrial modulation

Jaiswal¹,

Tripathi²,

ASSAIYA³

et al. 2022

Biocell

Self Cite

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) cell line MDA-MB-231 is known for Warburg metabolism and defects in mitochondria. On the other hand, dipeptidyl peptidase-IV (DPP-IV) inhibitors such as sitagliptin and vildagliptin and GLP-1 agonist exendin-4 are known to improve mitochondrial functions as well as biogenesis, but no study has evaluated the influence of these drugs on mitochondrial biogenesis on metastatic breast cancer cell line. We have recently reported anticancer effects of 5-aminoimidazole-4-carboxamide riboside on MDA-MB-231 cells via activation of AMP-dependent kinase (AMPK), which activates the downstream transcription factors PGC-1α, PGC-1β, or FOXO1 for mitochondrial biogenesis; above-mentioned incretin-based therapies are also known to activate AMPK. This study evaluated the effects of sitagliptin, vildagliptin, and exendin-4 on MDA-MB-231 cells and the underlying changes in mitochondrial biogenesis, were examined. Treatment with sitagliptin (100 µM), vildagliptin (100 µM), and exendin-4 (10 nM) for 72 h to MDA-MB-231 cells led to a decrease in viability indicated by MTT assay, cell migration by scratch, and transwell migration assays, accompanied with marginal reduction in cell numbers along with the apoptotic appearance, the rate of apoptosis, and decreased lactate content in conditioned medium. These changes in the cancer phenotype were accompanied by an increase in the mitochondrial DNA to nuclear DNA ratio, increased MitoTracker green and red staining, and increased expression of transcription factors PGC-1α, NRF-1, NRF-2, TFAM, and HO-1. Pre-treatment of cells with these incretin-based drugs followed by 48 h treatment with 1 µM doxorubicin increased doxorubicin sensitivity as observed by a decrease in viability by MTT assay. Thus, sitagliptin, vildagliptin, and exendin-4 exert their beneficial effects on TNBC cells via an increase in mitochondrial biogenesis that helps to switch Warburg metabolism into anti-Warburg effect. Therapeutic response was in the order of: sitagliptin > vildagliptin > exendin-4.

show abstract